IBDEI1G5 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,23400,1,4,0)
;;=4^I95.9
;;^UTILITY(U,$J,358.3,23400,2)
;;=^5008080
;;^UTILITY(U,$J,358.3,23401,0)
;;=Z51.81^^78^1009^25
;;^UTILITY(U,$J,358.3,23401,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23401,1,3,0)
;;=3^Therapeutic Drug Level Monitoring
;;^UTILITY(U,$J,358.3,23401,1,4,0)
;;=4^Z51.81
;;^UTILITY(U,$J,358.3,23401,2)
;;=^5063064
;;^UTILITY(U,$J,358.3,23402,0)
;;=D68.51^^78^1009^1
;;^UTILITY(U,$J,358.3,23402,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23402,1,3,0)
;;=3^Activated Protein C Resistance
;;^UTILITY(U,$J,358.3,23402,1,4,0)
;;=4^D68.51
;;^UTILITY(U,$J,358.3,23402,2)
;;=^5002358
;;^UTILITY(U,$J,358.3,23403,0)
;;=I82.402^^78^1009^2
;;^UTILITY(U,$J,358.3,23403,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23403,1,3,0)
;;=3^Acute Embolism/Thrombos Deep Veins Left Lower Extremity
;;^UTILITY(U,$J,358.3,23403,1,4,0)
;;=4^I82.402
;;^UTILITY(U,$J,358.3,23403,2)
;;=^5007855
;;^UTILITY(U,$J,358.3,23404,0)
;;=I82.401^^78^1009^3
;;^UTILITY(U,$J,358.3,23404,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23404,1,3,0)
;;=3^Acute Embolism/Thrombos Deep Veins Right Lower Extremity
;;^UTILITY(U,$J,358.3,23404,1,4,0)
;;=4^I82.401
;;^UTILITY(U,$J,358.3,23404,2)
;;=^5007854
;;^UTILITY(U,$J,358.3,23405,0)
;;=I82.890^^78^1009^4
;;^UTILITY(U,$J,358.3,23405,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23405,1,3,0)
;;=3^Acute Embolism/Thrombosis of Specified Veins
;;^UTILITY(U,$J,358.3,23405,1,4,0)
;;=4^I82.890
;;^UTILITY(U,$J,358.3,23405,2)
;;=^5007938
;;^UTILITY(U,$J,358.3,23406,0)
;;=D68.61^^78^1009^6
;;^UTILITY(U,$J,358.3,23406,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23406,1,3,0)
;;=3^Antiphospholipid Syndrome
;;^UTILITY(U,$J,358.3,23406,1,4,0)
;;=4^D68.61
;;^UTILITY(U,$J,358.3,23406,2)
;;=^185421
;;^UTILITY(U,$J,358.3,23407,0)
;;=I63.50^^78^1009^7
;;^UTILITY(U,$J,358.3,23407,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23407,1,3,0)
;;=3^Cerebral Infarction d/t Occls/Stenos of Cereb Artery
;;^UTILITY(U,$J,358.3,23407,1,4,0)
;;=4^I63.50
;;^UTILITY(U,$J,358.3,23407,2)
;;=^5007343
;;^UTILITY(U,$J,358.3,23408,0)
;;=I82.91^^78^1009^8
;;^UTILITY(U,$J,358.3,23408,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23408,1,3,0)
;;=3^Chronic Embolism/Thrombosis Unspec Vein
;;^UTILITY(U,$J,358.3,23408,1,4,0)
;;=4^I82.91
;;^UTILITY(U,$J,358.3,23408,2)
;;=^5007941
;;^UTILITY(U,$J,358.3,23409,0)
;;=I25.9^^78^1009^10
;;^UTILITY(U,$J,358.3,23409,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23409,1,3,0)
;;=3^Chronic Ischemic Heart Disease,Unspec
;;^UTILITY(U,$J,358.3,23409,1,4,0)
;;=4^I25.9
;;^UTILITY(U,$J,358.3,23409,2)
;;=^5007144
;;^UTILITY(U,$J,358.3,23410,0)
;;=D68.9^^78^1009^11
;;^UTILITY(U,$J,358.3,23410,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23410,1,3,0)
;;=3^Coagulation Defect,Unspec
;;^UTILITY(U,$J,358.3,23410,1,4,0)
;;=4^D68.9
;;^UTILITY(U,$J,358.3,23410,2)
;;=^5002364
;;^UTILITY(U,$J,358.3,23411,0)
;;=D68.8^^78^1009^12
;;^UTILITY(U,$J,358.3,23411,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23411,1,3,0)
;;=3^Coagulation Defects,Other Spec
;;^UTILITY(U,$J,358.3,23411,1,4,0)
;;=4^D68.8
;;^UTILITY(U,$J,358.3,23411,2)
;;=^5002363
;;^UTILITY(U,$J,358.3,23412,0)
;;=D68.318^^78^1009^13
;;^UTILITY(U,$J,358.3,23412,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23412,1,3,0)
;;=3^Hemorrhagic Disorder d/t Intrinsic Circ Anticoagulants
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1G5 3776 printed Sep 23, 2025@19:44:05 Page 2
IBDEI1G5 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,23400,1,4,0)
+2 ;;=4^I95.9
+3 ;;^UTILITY(U,$J,358.3,23400,2)
+4 ;;=^5008080
+5 ;;^UTILITY(U,$J,358.3,23401,0)
+6 ;;=Z51.81^^78^1009^25
+7 ;;^UTILITY(U,$J,358.3,23401,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,23401,1,3,0)
+10 ;;=3^Therapeutic Drug Level Monitoring
+11 ;;^UTILITY(U,$J,358.3,23401,1,4,0)
+12 ;;=4^Z51.81
+13 ;;^UTILITY(U,$J,358.3,23401,2)
+14 ;;=^5063064
+15 ;;^UTILITY(U,$J,358.3,23402,0)
+16 ;;=D68.51^^78^1009^1
+17 ;;^UTILITY(U,$J,358.3,23402,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,23402,1,3,0)
+20 ;;=3^Activated Protein C Resistance
+21 ;;^UTILITY(U,$J,358.3,23402,1,4,0)
+22 ;;=4^D68.51
+23 ;;^UTILITY(U,$J,358.3,23402,2)
+24 ;;=^5002358
+25 ;;^UTILITY(U,$J,358.3,23403,0)
+26 ;;=I82.402^^78^1009^2
+27 ;;^UTILITY(U,$J,358.3,23403,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,23403,1,3,0)
+30 ;;=3^Acute Embolism/Thrombos Deep Veins Left Lower Extremity
+31 ;;^UTILITY(U,$J,358.3,23403,1,4,0)
+32 ;;=4^I82.402
+33 ;;^UTILITY(U,$J,358.3,23403,2)
+34 ;;=^5007855
+35 ;;^UTILITY(U,$J,358.3,23404,0)
+36 ;;=I82.401^^78^1009^3
+37 ;;^UTILITY(U,$J,358.3,23404,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,23404,1,3,0)
+40 ;;=3^Acute Embolism/Thrombos Deep Veins Right Lower Extremity
+41 ;;^UTILITY(U,$J,358.3,23404,1,4,0)
+42 ;;=4^I82.401
+43 ;;^UTILITY(U,$J,358.3,23404,2)
+44 ;;=^5007854
+45 ;;^UTILITY(U,$J,358.3,23405,0)
+46 ;;=I82.890^^78^1009^4
+47 ;;^UTILITY(U,$J,358.3,23405,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,23405,1,3,0)
+50 ;;=3^Acute Embolism/Thrombosis of Specified Veins
+51 ;;^UTILITY(U,$J,358.3,23405,1,4,0)
+52 ;;=4^I82.890
+53 ;;^UTILITY(U,$J,358.3,23405,2)
+54 ;;=^5007938
+55 ;;^UTILITY(U,$J,358.3,23406,0)
+56 ;;=D68.61^^78^1009^6
+57 ;;^UTILITY(U,$J,358.3,23406,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,23406,1,3,0)
+60 ;;=3^Antiphospholipid Syndrome
+61 ;;^UTILITY(U,$J,358.3,23406,1,4,0)
+62 ;;=4^D68.61
+63 ;;^UTILITY(U,$J,358.3,23406,2)
+64 ;;=^185421
+65 ;;^UTILITY(U,$J,358.3,23407,0)
+66 ;;=I63.50^^78^1009^7
+67 ;;^UTILITY(U,$J,358.3,23407,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,23407,1,3,0)
+70 ;;=3^Cerebral Infarction d/t Occls/Stenos of Cereb Artery
+71 ;;^UTILITY(U,$J,358.3,23407,1,4,0)
+72 ;;=4^I63.50
+73 ;;^UTILITY(U,$J,358.3,23407,2)
+74 ;;=^5007343
+75 ;;^UTILITY(U,$J,358.3,23408,0)
+76 ;;=I82.91^^78^1009^8
+77 ;;^UTILITY(U,$J,358.3,23408,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,23408,1,3,0)
+80 ;;=3^Chronic Embolism/Thrombosis Unspec Vein
+81 ;;^UTILITY(U,$J,358.3,23408,1,4,0)
+82 ;;=4^I82.91
+83 ;;^UTILITY(U,$J,358.3,23408,2)
+84 ;;=^5007941
+85 ;;^UTILITY(U,$J,358.3,23409,0)
+86 ;;=I25.9^^78^1009^10
+87 ;;^UTILITY(U,$J,358.3,23409,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,23409,1,3,0)
+90 ;;=3^Chronic Ischemic Heart Disease,Unspec
+91 ;;^UTILITY(U,$J,358.3,23409,1,4,0)
+92 ;;=4^I25.9
+93 ;;^UTILITY(U,$J,358.3,23409,2)
+94 ;;=^5007144
+95 ;;^UTILITY(U,$J,358.3,23410,0)
+96 ;;=D68.9^^78^1009^11
+97 ;;^UTILITY(U,$J,358.3,23410,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,23410,1,3,0)
+100 ;;=3^Coagulation Defect,Unspec
+101 ;;^UTILITY(U,$J,358.3,23410,1,4,0)
+102 ;;=4^D68.9
+103 ;;^UTILITY(U,$J,358.3,23410,2)
+104 ;;=^5002364
+105 ;;^UTILITY(U,$J,358.3,23411,0)
+106 ;;=D68.8^^78^1009^12
+107 ;;^UTILITY(U,$J,358.3,23411,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,23411,1,3,0)
+110 ;;=3^Coagulation Defects,Other Spec
+111 ;;^UTILITY(U,$J,358.3,23411,1,4,0)
+112 ;;=4^D68.8
+113 ;;^UTILITY(U,$J,358.3,23411,2)
+114 ;;=^5002363
+115 ;;^UTILITY(U,$J,358.3,23412,0)
+116 ;;=D68.318^^78^1009^13
+117 ;;^UTILITY(U,$J,358.3,23412,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,23412,1,3,0)
+120 ;;=3^Hemorrhagic Disorder d/t Intrinsic Circ Anticoagulants
